Anti-angiogenic agents that target the VEGF pathway have demonstrated clinical benefit for a variety of malignancies, including colorectal, lung, glioblastoma, ovarian, and renal cell cancer [3, 10, 21-25]. Here, VEGFA is linked to renal cell adenocarcinoma.